ArticleHealth science reports2026
Impact of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use on Delirium Incidence in ICU Patients: A Retrospective Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: This investigation aimed at exploring the impact that the pre-existing use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) has on the incidence of delirium in patients within the intensive care unit (ICU). Methods: A retrospective investigation was conducted by utilizing the Medical Information Mart for Intensive Care dataset spanning from 2008 to 2022 (version 3.0). The primary endpoint of the study was the onset of delirium during the patients' 30-day stay in the ICU. Secondary endpoints incorporated the duration of ICU stay, the period of vasoactive drug administration, the incidence rate of acute kidney injury (AKI), and the necessity for continuous renal replacement therapy (CRRT). Results: A total of 15,666 patients were included in the analysis. Among them, 6,942 patients had no prior use of ACEIs or ARBs, 6,643 patients used ACEIs, and 2,081 patients used ARBs. The mean age of the patients was 66.2 ± 15.5 years, 56.4% were male, and 62% experienced delirium. Multivariable Cox regression models revealed significant hazard ratios (HRs) for patients who received ACEIs and ARBs. After adjusting for all confounding variables, both ACEIs and ARBs were significantly associated with a reduced risk of delirium (HR: 0.13, 95% CI: 0.13-0.15 for ACEIs; HR: 0.13, 95% CI: 0.12-0.14 for ARBs). The use of ACEIs was significantly associated with a lower risk of AKI (HR: 0.9, 95% CI: 0.82-0.98). Additionally, both ACEIs and ARBs were significantly associated with a decreased need for CRRT. Conclusion: Despite the significant association between the utilization of ACEIs or ARBs and a reduced incidence of delirium in critically ill patients, additional research is necessary to validate these results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.